• This study has uncovered an oncogenic role of EZH2 independent of its methyltransferase activity in NKTL.
Introduction
Nasal-type Natural Killer / T-cell lymphoma (NKTL) is an aggressive lymphoid malignancy associated with very poor survival. 1 A better understanding of the molecular abnormalities underlying this disease will provide important insights into the biology of this tumor; however, studies on NKTL is often limited by the lack of adequate tissue in small nasal biopsies and presence of necrosis in biopsy specimens. Although there is now more effective therapy, treatment is still completely reliant on radiotherapy and combinations of chemotherapy. 2, 3 We and others have recently performed whole genome gene expression studies and identify a number genes that are differentially expressed in NKTL as well as pathways which are activated in NKTL. EZH2, one of the genes identified in our study to be aberrantly over-expressed in NKTL, 4 is a H3K27-specific histone methyltransferase and a component of the polycomb repressive complex 2 (PRC2), which plays a key role in the epigenetic maintenance of repressive chromatin mark. EZH2 protein contains a catalytic domain (SET domain) at the COOH-terminus that provides the methyltransferase activity. The catalytic domain must partner with other non-catalytic proteins, such as EED and SUZ12, to form the PRC2 in order to attain robust histone methyltransferase activity. Genome-wide approaches have demonstrated the importance of the PRC2 complex in the transcriptional regulation through H3K27 methylation and gene repression. 5 For personal use only. on April 18, 2017. by guest www.bloodjournal.org From Published literature reveals a number of possible mechanisms of EZH2 upregulation in different types of human cancers. 6 It was shown that EZH2 expression can be transcriptionally activated by a fusion oncoprotein EWS-FLI1 in Ewing's sarcoma. 7 EZH2 expression in the breast tumor initiating cell population is particularly enhanced by hypoxia through HIF1a-mediated transactivation. 8 In addition to transcriptional regulation, EZH2 transcript is known to be regulated by tumor suppressor miRNAs. For example, miR-26a binds to and inhibits EZH2 transcript expression in B cell lymphoma.
9 miR-101 is frequently lost in metastatic prostate cancer thus releasing EZH2 from miR-101-mediated repression. 10 EZH2 can also be modulated by post-translational modifications through phosphorylation by AKT and CDK. 11, 12 To the best of our knowledge, the mechanism of EZH2 overexpression in NKTL has not yet been described.
High level of EZH2 expression is associated with aggressiveness and poor outcome in solid tumors such as prostate, breast and endometrial cancers. The oncogenic role of EZH2 overexpression in these tumor types has been extensively studied. In human B-cell malignancies, mutations of Y641 and A677 have been documented to be associated with profoundly increased activity for methylated H3K27, which may promote the development of lymphoma. [13] [14] [15] On the other hand, recent discoveries of recurrent somatic EZH2 mutations in myelodysplastic syndromes and myeloproliferative neoplasms indicate that inactivation of EZH2 may contribute to the pathogenesis of myeloid malignancies. 16, 17 Genetic inactivation of EZH2 is also identified in T cell acute lymphoblastic leukemia and the study suggests a tumor suppressor role for EZH2 in human leukemia by a hitherto unrecognized dynamic interplay between oncogenic 
Methods

Immunohistochemistry (IHC)
38 clinical cases of NKTL that fulfill the WHO diagnostic criteria were used for IHC studies. The clinicopathologic data of the cases are included in Supplementary Table 1. 27 cases were from the tissue microarray (TMA) used in our previous study (GEO accession number: GSE31377). 4 IHC was performed for EZH2, Ki67 and H3K27me3 on four-µm sections of NKTL using the conditions listed in Supplementary 
Primary NK cell isolation and retroviral transduction
Highly purified (90%-99%) normal human NK cells were isolated and cultured as previously described. 19 Retroviruses were generated by transfection of empty plasmid vector pMN-EGFP or vectors containing EZH2 using Fugene HD6 into Phoenixamphotropic packaging cells. At 48 h after transfection, the supernatants were collected and filtered. A total of 200,000 cells were mixed with 1.6 mL retroviral supernatant in 12-well plates with 10 μ g/mL Polybrene added. The infection was repeated at 72h after transfection.
Luciferase reporter assay
The CCND1 promoter construct pGL4-CCND1-Luc has been described previously.
20
Cells were harvested 24 hr after transfection and analyzed with the Dual Luciferase system (Promega). See the Supplemental Method and Materials for details.
Chromatin Immunoprecipitation (ChIP) assay
ChIP assays were performed as previously described. 21 See the Supplemental Method and Materials for details of the antibodies used and primer sequences.
Western Blotting
Cells were lysed in RIPA buffer and subjected to sonication. 
Results
EZH2 is over-expressed in NKTL
In our previously published genome-wide gene expression profiling (GEP) of extranodal nasal-type NKTL, 4 EZH2 transcript level was significantly higher in NKTL compared to normal NK cells ( Figure 1A ). In corroboration with the GEP findings, we observed a significant percentage of cases (61%) showing positive expression of EZH2 protein in the tumor cells in our 38 cases of NKTL (TMA or whole tissue sections) by IHC ( Figure S1 and Supplementary Table 3) , while the normal NK cells only showed a minimal level of EZH2 (staining in 5% or less of cells). Indeed, EZH2 positive samples have significantly higher EZH2 mRNA levels ( Figure 1B ). These data confirm that EZH2 is overexpressed in NKTL at both mRNA and protein levels.
Loss of miR-26 and miR-101 contributes to the EZH2 upregulation in NKTL
Next, we sought to identify the mechanisms leading to EZH2 upregulation in NKTL. The genomic locus containing EZH2 is not commonly amplified in NKTL 22 . In our previous miRNA expression profiling study, we found several miRNAs that were predicted to target EZH2 by various computational algorithms (Supplementary Figure S2A , left), we observed that EZH2 expression was effectively attenuated ( Figure S2A , right). These data suggest that EZH2 overexpression may be attributed to the deregulation of miR-101, miR-26a, and miR-26b in NK tumor cells.
MYC activation suppresses the expression of miR-26 and miR-101 in NKTL
As the genomic loci containing miR-101, miR-26a and miR-26b are not recurrently Figure S4 ) and increase in cell growth as measured by the MTS assay ( Figure 3C ). Both western blot ( Figure 3D ) and qRT-PCR analysis using a pair of primers that specifically amplifies the SET domain ( Figure S5 ) confirmed the ectopic expression of EZH2 SET∆ in transfected cells. The ability of EZH2 SET∆ to deplete the H3K27me3 was also validated ( Figure 3D and Figure S6C ). These results indicate that the pro-proliferative property of EZH2 in NKTL is not mediated by its histone methyltransferase activity.
EZH2 directly activates CCND1 transcription by binding to its promoter independent of its methyltransferase activity in NKTL
To better understand how EZH2 promotes proliferation in NK cell lines, we explored the mechanism by which EZH2 regulates cell cycle genes. Helin's study showed that suppression of EZH2 by RNAi significantly decreased positive regulators of cell proliferation such as G1/S-cyclins 27 , so it is tempting to speculate that EZH2 directly regulates the transcription of these genes by binding to their genomic locus. CCND1
transcript is reported to be upregulated in NKTL tissues compared to normal NK cells 28 and high expression of Cyclin D1 correlates with poor prognosis and decreased survival in NKTL. 29 We therefore examined whether the transcription of CCND1 is affected by EZH2 overexpression. Consistent with our findings on cell growth, qRT-PCR indicated that CCND1 mRNA levels increased substantially after EZH2 over-expression in NKYS ( Figure 4A ). Higher induction of CCND1 by EZH2-SET∆ could be explained by previous report that ectopic EZH2 SET∆ depletes endogenous EZH2 and consistently displays higher levels of protein accumulation compared to the ectopic EZH2 WT. 30 Next we evaluated whether EZH2 can activate the activity of CCND1 promoter in NKYS cells.
Co-transfection of the EZH2 WT expression vector with the pGL4-CCND1-Luc reporter
For personal use only. on April 18, 2017. by guest www.bloodjournal.org From resulted in considerable activation of CCND1 promoter activity ( Figure 4B ). Consistent with prior results, activation of luciferase activity was also observed in cells transfected with EZH2 SET∆ ( Figure 4B ). Collectively, these results indicate that EZH2 positively regulates CCND1 transcription independent of its histone methyltransferase activity.
We then address whether EZH2 binds to CCND1 promoter using ChIP-qPCR assays. Six pairs of primers, located sequentially along the proximal promoter, first exon, and intron 1 of CCND1 were used to quantify the ChIP-enriched DNA by real-time PCR ( Figure   4C ). A peak representing EZH2 binding was observed (≈33-fold above background) at a region very close to the transcriptional start site of CCND1 ( Figure 4D ). ChIP using a control IgG showed no significant enrichment over the entire surveyed region ( Figure   4D ). By performing ChIP assays using a His-Tag antibody in NKYS transfected with His-Tagged EZH2 SET∆, we showed that ectopically expressing EZH2 SET∆ resulted in significant enrichment of EZH2-DNA complexes which was even higher than EZH2 WT ( Figure 4E ). This effect is specific to the SET domain as EZH2 SANT domain deletion mutants abolished EZH2 transcriptional activity on CCND1 promoter ( Figure 4F ). Furthermore, the data from tumor samples that CCND1 mRNA levels correlates well with EZH2 mRNA levels is consistent with this finding ( Figure 4G ). Consistently, Western blot analyses showed that Cyclin D1 protein is expressed together with EZH2 in NK cell lines but not in normal NK cells ( Figure 4H ). Taken together, our findings identify CCND1 as a bona fide direct target of EZH2 in NKTL. Importantly, EZH2 acts as a transcriptional activator for CCND1 gene without requiring histone methylation
For personal use only. on April 18, 2017. by guest www.bloodjournal.org From 13 catalytic activity, which provides a mechanistic explanation for the pro-proliferative role of EZH2 SET∆ in NKTL.
Growth inhibition upon depletion of endogenous EZH2 can be rescued by exogenous EZH2 SET mutant
Given that EZH2 is of functional importance in NKTL, this raises the possibility that targeting EZH2 may be a feasible strategy in NKTL. We first investigated the effects of depleting EZH2 on cell growth. Using three different shRNAs targeting the EZH2 gene ( Figure 5D and Figure S7A ) in NKYS, we showed that depletion of EZH2 resulted in substantial decrease in cell numbers as revealed by the percentage of GFP+ cells ( Figure   5A ), and a specific concomitant decrease of Cyclin D1 expression but not other gene transcripts such as PRDM1 and IGF1 ( Figure 5B and Figure S8 ). This result strengthens the postulation that EZH2 is required for the expression of proliferative gene CCND1 and suggests that downregulation of Cyclin D1 is responsible for the reduction in cell growth in NKTL cells after EZH2 depletion. We next clarify if the reduction in cell growth is dependent on methyltransferase activity of EZH2. Since EZH2 SET∆ is immune to EZH2 shRNA-2, which targets the SET domain, EZH2 shRNA-2 only depleted endogenous wildtype EZH2 but not the EZH2 SET∆ after being introduced into the cells as expected ( Figure S7B ). Indeed, EZH2 SET∆ was able to prevent the reduction in cell number mediated by EZH2 shRNA-2 while reintroduction of EZH2 WT could not ( Figure 5C , left). These rescue experiments excluded the possibility that the cell death phenotype occurred due to off-target effect of EZH2 shRNA and at the same time confirming that the pro-survival effect of endogenous EZH2 does not require its enzymatic activity. Figure S12A) . Interestingly, the sensitivity of different cell lines to DZNep treatment seems to be related to the EZH2 expression levels ( Figure S12B ).
Discussion
The data presented here show that EZH2 is aberrantly over-expressed in NKTL, and that this is linked to Myc-mediated repression of miRNAs such as miR26 and miR101 that normally target and inhibit EZH2 expression. This regulatory network demonstrated in NKTL further strengthens the recently proposed model that MYC may stimulate EZH2 over-expression by repression of its negative regulatory miRNAs. 9 Importantly, EZH2 over-expression is functionally important in NKTL and the ability of EZH2 to promote proliferation in NKTL does not require its histone methyltransferase activity. Thus, our findings have uncovered for the first time a crucial and novel role for EZH2 in the control of cell proliferation. Given our finding, it is likely that this unconventional role of EZH2 seen in NTKL may represent a more general feature which may be also operational in other malignancies.
The best understood mechanism by which EZH2 exerts its oncogenic function is to induce gene repression through its effect on chromatin via its histone methyltransferase activity that requires the SET domain of EZH2. However, there has been emerging showed that EZH2 enzymatic function in AML is important and may be involved in deregulating metabolic pathways genes. 34 On the other hand, in the current study in NKTL, it is the non-enzymatic mechanism that seems important in driving cell cycle progression by activating CCND1 expression. The understanding of how EZH2 works as an oncogene in different cancers has important therapeutic implications. EZH2 is currently thought to be important in oncogenesis through its enzymatic activity, hence inhibitors in development are mostly targeting EZH2's enzymatic activity. Our study demonstrates that the oncogenic function of EZH2 may not always be dependent on its enzymatic activities. Small molecule drugs that block EZH2 enzymatic activity will therefore not work in these situations. This implies a need to review current therapeutic strategies. In view of EZH2's dual function in transcription activation and epigenetic repression, ideally, there is a need to identify tumors where EZH2 is predominantly acting through its enzymatic function as a histone methyltransferase, inhibiting the protective role of tumor suppressor genes, as well as tumors where EZH2 is predominantly acting through activation of genes involved in other oncogenic pathways.
This will ensure that the appropriate therapeutic strategy can be applied. Conversely, a compound that downregulates EZH2 protein may be effective in both scenarios. In this regard, therapeutic compounds which lead to EZH2 protein degradation rather than specific enzymatic inhibitors may be advantageous.
The pro-proliferative properties of EZH2 in NKTL support the rationale for using EZH2
inhibitors in the treatment of NKTL. Since targeting of EZH2 is an active area of drug For
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